{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:39:45Z","timestamp":1789609185646,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>AD is a progressive neurodegenerative disorder causing significant cognitive decline and impaired daily functioning. Current treatments offer only modest relief, and many amyloid-targeting therapies have failed, prompting exploration of alternative approaches such as PE with albumin replacement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This scoping review systematically maps the literature on PE with albumin replacement in AD management, focusing on outcomes, methodologies, and reported benefits and risks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search in PubMed, supplemented by reference scanning and hand-searching, identified studies involving PE with albumin replacement in AD patients. Data charting and critical appraisal were conducted using standardized tools.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven primary studies from the AMBAR (Alzheimer Management by Albumin Replacement) trial met the inclusion criteria, consistently reporting improvements in cognitive function, positive neuroimaging results, and favorable neuropsychiatric outcomes. For instance, one study found a significant slowing of cognitive decline (<jats:italic>p<\/jats:italic> &amp;lt;\u20090.05) among patients receiving PE with albumin replacement. Another study showed better preservation of hippocampal volume and improved brain perfusion metrics in the treatment group (<jats:italic>p<\/jats:italic> &amp;lt;\u20090.05). The intervention was generally well-tolerated with manageable side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PE with albumin replacement is a promising therapeutic approach for AD, warranting further investigation to confirm its efficacy and safety across broader settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Scoping review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/osf.io\/v6dez\/?view_only=1cd9637e7e0347d39713bf19aac0dfe8<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1443132","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T04:37:02Z","timestamp":1727671022000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The use of plasma exchange with albumin replacement in the management of Alzheimer\u2019s disease: a scoping review"],"prefix":"10.3389","volume":"15","author":[{"given":"Yahveth","family":"Cantero-Fortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/alz.12328","article-title":"2021 Alzheimer's disease facts and figures","volume":"17","year":"2021","journal-title":"Alzheimers Dement"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1474-4422(24)00329-6","article-title":"The evolving paradigm of Alzheimer's disease diagnosis","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","article-title":"Alzheimer's disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimers Dement"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fnagi.2018.00100","article-title":"Targeting Beta-amyloid at the CSF: a new therapeutic strategy in Alzheimer's disease","volume":"10","author":"Menendez-Gonzalez","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"ref8","first-page":"e12179","article-title":"Alzheimer\u2019s disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimers Dement"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1126\/science.aau0437","article-title":"Alzheimer's disease: the right drug, the right time","volume":"362","author":"Golde","year":"2018","journal-title":"Science"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/alz.12137","article-title":"A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: primary results of the AMBAR study","volume":"16","author":"Boada","year":"2020","journal-title":"Alzheimers Dement"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/alz.12477","article-title":"Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study","volume":"18","author":"Boada","year":"2022","journal-title":"Alzheimers Dement"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jca.21470","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"ref13","first-page":"8","article-title":"Complications of therapeutic plasma exchange in patients with neurological disorders","volume":"19","author":"Afzali","year":"2020","journal-title":"Curr J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/(sici)1098-1101(2000)15:1\/2<74::aid-jca6>3.0.co;2-o","article-title":"Therapeutic apheresis in neurological disorders","volume":"15","author":"Weinstein","year":"2000","journal-title":"J Clin Apher"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JAD-170693","article-title":"Longitudinal neuroimaging analysis in mild-moderate Alzheimer\u2019s disease patients treated with plasma exchange with 5% human albumin","volume":"61","author":"Cuberas-Borr\u00f3s","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3233\/JAD-160565","article-title":"Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-\u03b2 concentrations and cognition outcomes in Alzheimer\u2019s disease patients: a multicenter, randomized, Controlled Clinical Trial","volume":"56","author":"Boada","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1007\/s00259-022-05915-5","article-title":"Neuroimaging analyses from a randomized controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study","volume":"49","author":"Cuberas-Borr\u00f3s","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trci.2019.01.001","article-title":"Plasma exchange for Alzheimer's disease management by albumin replacement (AMBAR) trial: study design and progress","volume":"5","author":"Boada","year":"2019","journal-title":"Alzheimers Dement"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/jca.22026","article-title":"Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study","volume":"38","author":"Boada","year":"2023","journal-title":"J Clin Apher"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.3390\/jcm9103211","article-title":"Apheresis in Neurological Disorders","volume":"9","author":"Dorst","year":"2020","journal-title":"J Clin Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.3390\/jcm9092874","article-title":"Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases","volume":"9","author":"Dorst","year":"2020","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"18(S10)","DOI":"10.1002\/alz.066811","article-title":"Impact of therapeutic plasma exchange on amyloid plaque load and vascular health in APP\/PS1 mice","volume":"18","author":"Cover","year":"2022","journal-title":"Alzheimers Dement"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/ph13020028","article-title":"Therapeutic plasmapheresis with albumin replacement in Alzheimer's disease and chronic progressive multiple sclerosis: a review","volume":"13","author":"Navarro-Mart\u00ednez","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/14728214.2016.1241232","article-title":"Emerging drugs to reduce abnormal beta-amyloid protein in Alzheimer\u2019s disease patients","volume":"21","author":"Panza","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/1744-9987.14002","article-title":"Impact of therapeutic and low volume plasma exchange on clinical laboratory parameters in patients treated for Alzheimer's disease from the AMBAR study","volume":"27","author":"Grifols","year":"2023","journal-title":"Ther Apher Dial"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1002\/alz.12739","article-title":"Plasma exchange: an effective method to eliminate neurotoxic lipophilic chemicals from blood","volume":"18","author":"Kang","year":"2022","journal-title":"Alzheimers Dement"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e064422","DOI":"10.1002\/alz.064422","article-title":"Benefit of plasma exchange with albumin replacement on individual items of the quality of life-Alzheimer\u2019s disease score","volume":"19","author":"Stewart","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/26348535221131685","article-title":"Conventional therapeutic plasma exchange versus low volume plasma exchange in chronic pathologies: potential benefit in Alzheimer\u2019s disease","volume":"16","author":"Escolar","year":"2022","journal-title":"Plasmatology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.14283\/jpad.2016.112","article-title":"Precision medicine - the golden gate for detection, treatment and prevention of Alzheimer's disease","volume":"3","author":"Hampel","year":"2016","journal-title":"J Prev Alzheimers Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.3233\/JAD-179932","article-title":"Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology","volume":"64","author":"Hampel","year":"2018","journal-title":"J Alzheimers Dis"}],"updated-by":[{"DOI":"10.3389\/fneur.2024.1509655","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000}}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1443132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T14:15:01Z","timestamp":1730211301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1443132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":32,"alternative-id":["10.3389\/fneur.2024.1443132"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1443132","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fneur.2024.1509655","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"article-number":"1443132"}}